Dr. Reddy's Loses Bid To Invalidate Teva Patents

Law360 (March 5, 2008, 12:00 AM EST) -- A district judge has allowed Teva Pharmaceutical Industries Ltd. to proceed with its lawsuit to bar Dr. Reddy's Laboratories Inc. from marketing a generic version of GlaxoSmithKline Inc.'s congestive heart failure drug Coreg.

Dr. Reddy's had asked the U.S. District Court for the District of New Jersey in October for a partial summary judgment that the first two claims of one of the patents at issue, known as the '008 patent, were invalid because they were anticipated by prior art.

Teva, an Israel-based generic drug company,...
To view the full article, register now.